← Oncology Approval Tracker

FDA DECISION ·

Nyvepria

pegfilgrastim-apgf · Hospira

Biosimilar approvalBiosimilarChemotherapy-associated febrile neutropenia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with nonmyeloid cancers receiving myelosuppressive anticancer drugs with a clinically significant risk of febrile neutropenia, to reduce infections manifested by febrile neutropenia.

LAMPGEN ANALYSIS

Why it matters

Added a pegfilgrastim biosimilar for chemotherapy-related infection prevention.

What research teams should watch

Keep administration timing tied to chemotherapy and record the exact biologic dispensed.

PRIMARY RECORDS

Sources